Eczema and Inflammation: The Immune Imbalance Behind Atopic Dermatitis

Atopic dermatitis (AD), commonly called eczema, is the most prevalent chronic inflammatory skin disease, affecting 15 to 20 percent of children and 1 to 3 percent of adults in high-income countries. Its prevalence has increased two- to three-fold in developed countries over the past 50 years, a trend that parallels the rise of allergic and autoimmune conditions broadly and points to environmental and microbiome changes as major contributors. Despite its reputation as a childhood skin condition, atopic dermatitis can be severe and lifelong, and it represents far more than a cosmetic or dermatological problem.

The same immune dysregulation that drives atopic dermatitis in the skin is part of a broader atopic diathesis, a constitutional tendency toward inflammatory overreaction that underlies food allergies, asthma, and allergic rhinitis in many patients. Understanding this systemic inflammatory context is essential for managing the condition effectively.

Th2 Skewing, Barrier Dysfunction, and the Itch-Scratch Cycle

Atopic dermatitis involves two primary abnormalities: a defective skin barrier and a Th2-skewed immune response. The skin barrier defect stems partly from loss-of-function mutations in filaggrin, a structural protein essential for forming the skin's outer protective layer. Filaggrin mutations are found in approximately 30 percent of European AD patients and are among the strongest genetic risk factors for the condition. Defective filaggrin production creates a leaky barrier that allows allergens, irritants, and microorganisms to penetrate into the dermis, triggering immune responses that would not occur in intact skin.

The immune response in AD is dominated by Th2 cytokines, particularly IL-4, IL-13, and IL-31. IL-4 and IL-13 inhibit the production of antimicrobial peptides and structural proteins needed to repair the skin barrier, perpetuating the leakiness that allows continued allergen exposure. IL-31 directly activates itch-sensing neurons in the skin, producing the intense pruritus that drives scratching. Scratching further damages the barrier, allows more allergen and microbial entry, and amplifies the Th2 inflammatory response. This itch-scratch cycle is both the most distressing clinical feature of AD and a powerful perpetuator of the underlying inflammatory biology.

The Skin Microbiome and Staphylococcal Colonization

The skin microbiome in atopic dermatitis is profoundly dysbiotic. Lesional AD skin is dominated by Staphylococcus aureus, which colonizes more than 90 percent of AD patients at levels far higher than in healthy skin. S. aureus contributes to AD through multiple mechanisms: its toxins act as superantigens that directly activate T-cells and mast cells, amplifying the Th2 inflammatory response; its biofilm disrupts the skin barrier; and its virulence factors sensitize the skin to other allergens. Clinical flares of AD are frequently precipitated by increases in S. aureus colonization density.

Commensal bacteria that are normally protective, particularly Staphylococcus epidermidis, are depleted in AD skin. S. epidermidis produces antimicrobial peptides that normally suppress S. aureus and other pathogens, and it promotes regulatory T-cell activity in the skin that dampens inflammatory overreaction to commensal exposures. The loss of this protective commensal microbiome is both a consequence of Th2-mediated antimicrobial peptide suppression and a perpetuator of the inflammatory state. Microbiome restoration approaches, including topical probiotic application and dilute bleach baths that reduce S. aureus colonization without eliminating commensals, have shown efficacy in several clinical trials.

Systemic Inflammatory Markers in Atopic Dermatitis

Despite being primarily a skin disease, moderate to severe atopic dermatitis is associated with measurable systemic inflammation. Studies find elevated circulating IL-4, IL-13, IL-31, thymic stromal lymphopoietin (TSLP), and IgE levels in AD patients, reflecting systemic rather than purely local Th2 activation. CRP is modestly elevated in severe AD and correlates with disease severity scores. TSLP and IL-33, cytokines produced by barrier-stressed epithelial cells, enter systemic circulation and have immunological effects on cells throughout the body, explaining some of the extra-cutaneous features of atopic disease.

The atopic march, the sequential development of eczema in infancy followed by food allergy, asthma, and allergic rhinitis in later childhood, represents a progression of systemic Th2 inflammatory dysregulation from one tissue to another over time. Children with early-onset severe eczema have a substantially higher lifetime risk of asthma than those without eczema, partly because the same Th2 immune skewing that drives skin inflammation also sensitizes the airways to allergen-driven inflammatory overreaction. This shared systemic immune dysregulation is why treating eczema effectively, particularly in early life, may have preventive implications for downstream allergic and inflammatory conditions.

Managing Eczema Through Immune and Environmental Strategies

The most important intervention for reducing AD inflammation is aggressive skin barrier repair. Twice-daily application of emollients, ideally within 3 minutes of bathing while the skin is still damp, significantly reduces transepidermal water loss, allergen penetration, and inflammatory stimulus in controlled trials. Studies have found that consistent emollient use from birth in high-risk infants reduces eczema incidence by up to 50 percent, supporting the hypothesis that barrier protection prevents the sensitization cascade before it begins.

Diet plays a role in some but not all AD patients. Food allergies, particularly to egg, milk, wheat, soy, and peanuts, trigger or worsen eczema in approximately 30 percent of children with moderate to severe disease. Identifying and eliminating relevant food triggers reduces inflammatory burden in these patients. Probiotic supplementation during pregnancy and early infancy has shown modest but consistent benefits for AD prevention in high-risk populations in meta-analyses. For adults with severe AD, dupilumab, a biologic that blocks IL-4 and IL-13 signaling, has transformed disease management by addressing the core Th2 immune dysregulation directly, producing dramatic skin clearance and reductions in systemic Th2 inflammatory markers.